SCHEMBL945963

SCHEMBL945963

C1CNCC(CCN2CCOCC2)[N]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HRH3 Q9Y5N1 3/20 0.35
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 2/20 0.34
MAPK1 P28482 2/20 0.33
SIGMAR1 Q99720 2/20 0.33
CYP1A2 P05177 2/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
HTR2A P28223 1/20 0.33
SCN1A P35498 1/20 0.33
HTR2B P41595 1/20 0.33
KCNH2 Q12809 1/20 0.33
SCN2A Q99250 1/20 0.33
SCN3A Q9NY46 1/20 0.33
HPGD P15428 1/20 0.33
DUSP3 P51452 1/20 0.33
LMNA P02545 2/20 0.32
USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL947556 0.85 CXCR4 (0.39) HRH3CYP1A2HRH1
SCHEMBL5157997 0.83 GAA (0.31) ALDH1A1GAA
SCHEMBL947501 0.83 CXCR4 (0.38) SMN1; SMN2HRH3MAPK1CYP1A2HRH1
SCHEMBL950032 0.83 CXCR4 (0.40) KEAP1SMN1; SMN2HRH3ALDH1A1MAPK1
SCHEMBL947318 0.75 CXCR4 (0.40) SMN1; SMN2HRH3MAPK1CYP1A2HRH1
SCHEMBL3557649 0.72 GLA (0.44) SMN1; SMN2ALDH1A1LMNAGLAMAPT
SCHEMBL18579046 0.71 GNAO1 (0.37) KEAP1SMN1; SMN2ALDH1A1KDM4ECYP1A2
SCHEMBL18505991 0.71 GNAO1 (0.37) KEAP1SMN1; SMN2ALDH1A1KDM4ECYP1A2
SCHEMBL18505992 0.71 GNAO1 (0.37) KEAP1SMN1; SMN2ALDH1A1KDM4ECYP1A2
SCHEMBL713471 0.71 L3MBTL1 (0.40) SMN1; SMN2ALDH1A1KDM4ELMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989446-B2 4-amino 5-cyanopyrimidine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-08-02 US disclosed
US-20110009620-A1 4-Amino-5-cyanopyrimidine derivatives OTSUKA PHARMACEUTICAL CO., LTD. 2011-01-13 US disclosed
US-7834002-B2 4-amino-5-cyanopyrimidine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-11-16 US disclosed
US-20080182854-A1 4-Amino-5-Cyanopyrimidine Derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-07-31 US disclosed
EP-1740574-B1 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES OTSUKA PHARMA CO LTD (JP) 2007-06-27 EP disclosed
EP-1740574-A2 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES Otsuka Pharmaceutical Company, Limited (JP) 2007-01-10 EP disclosed
WO-2005105778-A2 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009620-A1 4-Amino-5-cyanopyrimidine derivatives ADORA2A, ADORA1, ADORA3 KEAP1 846/4885SMN1; SMN2 4598/4885HRH3 1003/4885
US-20080182854-A1 4-Amino-5-Cyanopyrimidine Derivatives ADORA2A, ADORA1, ADORA3 KEAP1 846/4885SMN1; SMN2 4598/4885HRH3 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.